Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.46 |
| ▸ | MITF | O75030 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | GFER | P55789 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | LTA4H | P09960 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | GPR88 | Q9GZN0 | 1/20 | 0.43 |
| ▸ | AURKA | O14965 | 1/20 | 0.43 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5559775 | 1.00 | ALDH1A1 (0.46) | ALDH1A1MITFSMN1; SMN2GFERHTT | |
| SCHEMBL5844785 | 1.00 | ALDH1A1 (0.46) | ALDH1A1MITFSMN1; SMN2GFERHTT | |
| SCHEMBL17574260 | 0.98 | ALDH1A1 (0.45) | ALDH1A1MITFSMN1; SMN2GFERHTT | |
| SCHEMBL14452757 | 0.98 | ALDH1A1 (0.45) | ALDH1A1MITFSMN1; SMN2GFERHTT | |
| SCHEMBL9677137 | 0.98 | ALDH1A1 (0.45) | ALDH1A1MITFSMN1; SMN2GFERHTT | |
| SCHEMBL14452012 | 0.96 | GAA (0.44) | ALDH1A1MITFSMN1; SMN2GFERHTT | |
| SCHEMBL2953080 | 0.90 | UTS2R (0.44) | LTA4HOPRK1 | |
| SCHEMBL1541502 | 0.86 | GAA (0.61) | ALDH1A1GFERPOLBGAACYP2D6 | |
| SCHEMBL1239640 | 0.85 | POLB (0.50) | ALDH1A1MITFSMN1; SMN2HTTATM | |
| SCHEMBL8720321 | 0.84 | HRH3 (0.45) | ALDH1A1MITFSMN1; SMN2RAB9APAX8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5472961-A | Acetamides | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1995-12-05 | — | — | US | claimed |
| EP-3013812-B1 | KAPPA OPIOID AGONISTS AND USES THEREOF | NEKTAR THERAPEUTICS (US) | 2019-10-16 | — | — | EP | disclosed |
| EP-3237388-B1 | N-METHYL-N-(1-PHENYL-2-(1-PYRROLIDINYL)ETHYL)-2-AMINOPHENYLACETAMIDE DERIVATIVES AGONISTS FOR THE KAPPA OPIOID RECEPTOR | NEKTAR THERAPEUTICS (US) | 2019-07-03 | — | — | EP | disclosed |
| CN-104271552-B | Substituted heterocyclic acetamides as KAPPA Opioid Receptor (KOR) agonists | 雷迪博士实验室有限公司 | 2017-08-08 | — | — | CN | disclosed |
| EP-2961745-B1 | PHENYLPYRAZOLE DERIVATIVES AS POTENT ROCK1 AND ROCK2 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-03-29 | — | — | EP | disclosed |
| US-9487510-B2 | Substituted heterocyclic acetamides as kappa opioid receptor (KOR) agonists | DR. REDDY'S LABORATORIES LTD. (IN) | 2016-11-08 | — | — | US | disclosed |
| US-9458110-B2 | Phenylpyrazole derivatives as potent ROCK1 and ROCK2 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-10-04 | — | — | US | disclosed |
| US-20160016910-A1 | PHENYLPYRAZOLE DERIVATIVES AS POTENT ROCK1 AND ROCK2 INHIBITORS | BRISTOL-MEYERS SQUIBB COMPANY (US) | 2016-01-21 | — | — | US | disclosed |
| US-9126944-B2 | Phenylpyrazole derivatives as potent ROCK1 and ROCK2 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-09-08 | — | — | US | disclosed |
| US-20150031685-A1 | SUBSTITUTED HETEROCYCLIC ACETAMIDES AS KAPPA OPIOID RECEPTOR (KOR) AGONISTS | Dr. Reeddy's Laboratories Ltd. (IN) | 2015-01-29 | — | — | US | disclosed |
| US-6054445-A | KAPPA OPIOID AGONIST ACTIVITY; ANALGESICS AND ANTI-PRURITIC AGENTS | ADOLOR CORPORATION (US) | 2000-04-25 | — | — | US | disclosed |
| WO-2000014065-A1 | KAPPA AGONIST COMPOUNDS AND PHARMACEUTICAL FORMULATIONS THEREOF | ADOLOR CORPORATION (US) | 2000-03-16 | — | — | WO | disclosed |
| CN-1041087-C | Arylacetamides | MERCK PATENT AG (DE) | 1998-12-09 | — | — | CN | disclosed |
| EP-0569802-B1 | Arylacetamides | MERCK PATENT GMBH (DE) | 1998-07-15 | — | — | EP | disclosed |
| US-5532266-A | Acrylacetamides | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1996-07-02 | — | — | US | disclosed |
| CN-1121072-A | Acetamides | MERCK PATENG GES MIT BESCHRANK (DE) | 1996-04-24 | — | — | CN | disclosed |
| US-5472961-A | Acetamides | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1995-12-05 | — | — | US | disclosed |
| CN-1079219-A | Arylacetamide | MERCK PATENT GMBH (DE) | 1993-12-08 | — | — | CN | disclosed |
| EP-0569802-A1 | Arylacetamides | MERCK PATENT GmbH (DE) | 1993-11-18 | — | — | EP | disclosed |
| EP-0374756-A2 | Nitrogen-containing cyclic compounds | MERCK PATENT GmbH (DE) | 1990-06-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150031685-A1 | SUBSTITUTED HETEROCYCLIC ACETAMIDES AS KAPPA OPIOID RECEPTOR (KOR) AGONISTS | OPRK1, OPRL1, OPRD1 | ALDH1A1 816/4885MITF 4036/4885SMN1; SMN2 1098/4885 |
| US-20160016910-A1 | PHENYLPYRAZOLE DERIVATIVES AS POTENT ROCK1 AND ROCK2 INHIBITORS | ROCK1, ROCK2, MYLK | ALDH1A1 2675/4885MITF 1912/4885SMN1; SMN2 645/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.